Rep. Kevin Hern Sells Icon Plc (NASDAQ:ICLR) Shares

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Icon Plc (NASDAQ:ICLR). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Icon stock on August 14th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.

Icon Trading Down 1.0%

Shares of NASDAQ ICLR opened at $159.84 on Thursday. The company’s 50 day simple moving average is $168.10 and its 200 day simple moving average is $134.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market capitalization of $12.24 billion, a P/E ratio of 37.52, a P/E/G ratio of 6.68 and a beta of 1.20. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.55 by $0.01. The business had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $3.26 EPS. On average, analysts predict that Icon Plc will post 9.58 EPS for the current year.

Insider Buying and Selling

In other Icon news, CFO Nigel Bernard John Clerkin sold 2,267 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $372,445.43. Following the completion of the sale, the chief financial officer owned 5,881 shares of the company’s stock, valued at approximately $966,189.49. This represents a 27.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Anne Clem Whitaker sold 841 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the transaction, the director owned 891 shares of the company’s stock, valued at approximately $146,382.39. The trade was a 48.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 9,531 shares of company stock valued at $1,565,764. Corporate insiders own 44.00% of the company’s stock.

Institutional Investors Weigh In On Icon

Several hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC raised its stake in shares of Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the period. GAMMA Investing LLC raised its position in Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after purchasing an additional 69 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after buying an additional 93 shares during the period. Finally, Westpac Banking Corp lifted its holdings in Icon by 9.9% during the 4th quarter. Westpac Banking Corp now owns 1,146 shares of the medical research company’s stock worth $209,000 after buying an additional 103 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ICLR has been the topic of several research analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. Citigroup boosted their price objective on Icon from $165.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Truist Financial reaffirmed a “buy” rating and issued a $209.00 price objective (up from $207.00) on shares of Icon in a report on Friday, July 31st. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. Finally, Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Icon currently has an average rating of “Hold” and a consensus target price of $170.40.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.